NCT06306872
A Clinical Trial to Evaluate the Relative Bioavailability of New and Old ABSK-011 Capsules
A Single-center, Open-label, Multi-period Study to Evaluate the Relative Bioavailability of New and Old ABSK-011 Capsules and the Effects of Low-fat Diet, High-fat Diet and Omeprazole Magnesium Enteric-coated Tablets on the Pharmacokinetic Profile of New ABSK-011 Capsules in Healthy Subjects
Abbisko Therapeutics Co, Ltd·Phase 1·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →Study focus
- Disease/Condition
- Healthy Subjects
- Drug/Device/Intervention
- Sequence A ABSK-011
- Study type
- Interventional
- Intervention type
- drug
Sponsor & location
- Primary sponsor
- Abbisko Therapeutics Co, Ltd
- Location
- Wuxi, China
Timeline & enrollment
- Phase
- Phase 1
- Start date
- Feb 23, 2024
- End date
- Dec 31, 2024
- Enrollment
- 73 participants
Primary outcome
Cmax,AUC,tmax
Summary
The main objective of which is to evaluate the relative bioavailability and PK
 characteristics of new and old ABSK-011 capsules in a single oral dose
ICD-10 classifications
Occupational health examinationSeeking and accepting physical, nutritional and chemical interventions known to be hazardous and harmfulRoutine child health examinationExamination and observation for other reasons
Data source
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06306872
- Type
- Non-Device Trial
About this record
Access comprehensive clinical trial information for NCT06306872 through Pure Global AI's free database. This Phase 1 trial is sponsored by Abbisko Therapeutics Co, Ltd and is currently Recruiting. The study focuses on Healthy Subjects. Target enrollment is 73 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.